25 May 2021 | Online: BST (UTC+1)
Oncolytic Viruses Symposium25 May 2021 | Online: BST (UTC+1)

The latest data & strategies impacting the development of oncolytic viruses, from virus engineering and biomarker development through to navigating clinical trials

The programme brings together international pharmaceutical organisations, leading biotech companies and globally renowned academic institutions specialising in the development of oncolytic viruses

Download Agenda

Full details on the Symposium including the presentations, topic areas and confirmed speakers will be released in the conference brochure in the coming weeks

Book Online

Registration is now open for the Oncolytic Viruses Symposium. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts working in immunotherapy, autoimmunity and immuno-oncology

Oncolytic Viruses Symposium
is sponsored by

Programme

Benefits to Attending...

  • Hear from and meet with the leading figures in the oncolytic virus field, offering innovative case studies on the latest strategies from discovery through to the clinic
  • Interact with fellow attendees and speakers during the live Q&As, taking place across the day and through our interactive panel discussion on ‘The challenges for oncolytic virus therapies in clinical trials’
  • Explore how companies are accelerating oncolytic viruses to the clinic. Presentations consider the best strategies, including combination virotherapies, likely to succeed in the clinic and deliver maximum patient benefit
  • Gain insights into how oncolytic viruses can trigger an immune response in the body against cancer, with consideration of the mechanistics of viruses, tumour biology and the tumour microenvironment
  • View new platforms to tackle key challenges facing oncolytic virus therapies, including immune response, tumour resistance and gene selection

Agenda at a Glance

Morning Session:
Engineering & Translational Strategies To Develop Oncolytic Virus Immunotherapy

  • Mechanistic understanding of viruses and tumour biology
  • Engineering and optimization strategies to improve delivery, oncolysis and specificity of therapies
  • Preclinical validation to ensure efficacy of therapies before clinical trials
  • Targeting the tumour microenvironment
  • Understanding the importance of therapeutic gene selection


Afternoon Session:
Accelerating Oncolytic Virus Immunotherapy To The Clinic

  • Challenges of safety and immune response to therapies in clinical trials
  • Combination virotherapy strategies to enhance therapeutic results
  • Delivering oncolytic viruses into solid tumours
  • Developing biomarkers for therapies in clinical trials
  • Selection of the best route of administration for immunotherapies in clinical trials

Confirmed Speakers

The online Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry perspectives.

Romain Micol

Romain Micol

Combined Therapeutics

Inanç Ortaç, DevaCell

Inanç Ortaç

DevaCell Inc.

Lorena Lerner, Oncorus

Lorena Lerner

Oncorus

Patrik Erlmann ViraTherapeutics GmbH

Patrik Erlmann

ViraTherapeutics GmbH

Victor Cervera-Carrascon, Tilt Biotherapeutics

Víctor Cervera Carrascón

TILT Biotherapeutics

Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As

Digital Networking Opportunities

Connect directly with other event registrants around the world through direct 1-2-1 chat, video chat and group discussion

WuXi AppTec

Event Sponsor

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,200 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.” 

https://www.wuxiapptec.com/  

Advanced Bioscience Laboratories

Event Sponsor

ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieuxwhich fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing. 

As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedInTwitter and Facebook and subscribe to our mailing list.